Immune Checkpoint Inhibitor Outcomes in NSCLC Across Populations and Practice Settings
Open Access
- 5 January 2026
- journal article
- Published by Elsevier in JTO Clinical and Research Reports
- Vol. 7 (4) , 100952
Abstract
No abstract availableKeywords
Funding Information
- University of Texas Southwestern Medical Center
- Cancer Prevention and Research Institute of Texas (RP220542)
This publication has 29 references indexed in Scilit:
- Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical TrialsJAMA Oncology, 2018
- Effect of hospital safety net designation on treatment use and survival in hepatocellular carcinomaCancer, 2017
- Safety-net Hospitals Face More Barriers Yet Use Fewer Strategies to Reduce ReadmissionsMedical Care, 2017
- The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA: A Cancer Journal for Clinicians, 2017
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Evaluating Area‐Based Socioeconomic Status Indicators for Monitoring Disparities within Health Care Systems: Results from a Primary Care NetworkHealth Services Research, 2014
- Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III Non–Small-Cell Lung CancerClinical Lung Cancer, 2013
- Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse PopulationJournal of Thoracic Oncology, 2010
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987